# Sean Stiefel

> Sean Stiefel is a Series A investor at Navy Capital (Newyork) backing Cannabis and Medical. See 3 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Navy Capital](https://shizune.co/investors/profile/navy-capital)
- Location: Newyork, United Kingdom
- Total investments: 3
- Last investment: Jun 2021
- Lead investor: 67%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/sean-stiefel-6b20359/
- X (Twitter): https://twitter.com/seanstiefel
- Website: https://x.com/seanstiefel
- Facebook: https://www.facebook.com/sean.stiefel

Sean Stiefel is a Series A investor at Navy Capital in Newyork focused on Cannabis and Medical. Sean Stiefel is the Founder and CEO of Navy Capital. He was the former Associate at Millennium Management.Sean Stiefel founded Navy Capital in 2014, where he manages a long/short portfolio structured to minimize beta to the overall market by using bottom-up and fundamental analysis. Prior to founding Navy Capital, Mr. Stiefel was a researchanalyst and trader for Northwoods Capital Management Partners, a global long/short fund with a fundamental value and special situations investment strategy. Mr. Stiefel had previously served as an associate within an equity long/short fund at Millennium Partners, and he began his career as an equities trading analyst for Barclays Capital. He is a graduate of the University of Southern California’s Marshall School of Business.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Cannabis | 2 | 67% |
| Medical | 1 | 33% |
| Wellness | 1 | 33% |
| Biotechnology | 1 | 33% |
| Manufacturing | 1 | 33% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 1 | 33% |
| Funding Round | 1 | 33% |
| Post-IPO Equity | 1 | 33% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 2 | 67% |
| Germany | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Sanity Group | Sanity Group is a holistic European Cannabis company focusing on health, wellbeing, and scientific research. To utilize the full potential of its health benefits, Sanity Group is investing in fundamental research of the cannabis plant and its active ingredients as well as in specific areas of application.It was founded in 2018 and headquarteredin Berlin, Germany. | $44.2M | Series A | Jun 15, 2021 |  |
| MariMed | MariMed is an industry leader in the design, development, operation. | $14.7M | Post-IPO Equity | Nov 27, 2018 |  |
| F/ELD | F/ELD is a Los Angeles-based cannabis brand focused on the "ultra premium" portion of the cannabis market. With the recent explosive growth in consumer facing brands for the cannabis industry, there have been a plethora of companies coming to market with products targeted towards the "mainstream" recreational consumer.F/ELD focuses on the upper echelon - customers who are focused on quality above all else. Led by a team with a combined 30+ years of experience in the cannabis industry, F/ELD is primed to be a market leader in the multi billion dollar cannabis industry. | $6M |  | Sep 20, 2018 |  |

3 of 3 investments shown.

## Co-investors
- [German Media Pool](https://shizune.co/investors/profile/gmpvc-german-media-pool) — VC Fund, 1 deal together
- [redalpine](https://shizune.co/investors/profile/redalpine-venture-partners) — VC Fund, 1 deal together
- [SOJE Capital](https://shizune.co/investors/profile/soje-capital) — VC Fund, 1 deal together

## About Navy Capital

VC Fund · New York, United States

Navy Capital’s research-oriented, fundamentally-driven investment process focuses on identifying attractive opportunities within the legal cannabis space. Navy Capital seeks to find the best in class businesses within key verticals of the global cannabis industry. Those verticals include Consumer, Healthcare, Technology, Industrials, andAgriculture.

3 contacts available at Navy Capital.

| Name | Title | Profile |
| --- | --- | --- |
| Chetan Gulati | Partner and Head of Research | https://shizune.co/investors/profile/chetan-gulati |
| John Kaden | Managing Partner & CIO | https://shizune.co/investors/profile/john-kaden |
| Sean Stiefel | Founder and CEO | https://shizune.co/investors/profile/sean-stiefel |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Sean Stiefel invest in?

Sean Stiefel invests primarily in Cannabis, Medical and Wellness startups, most often at Series A and Funding Round stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Sean Stiefel last invest?

The most recent investment recorded for Sean Stiefel closed in Jun 2021. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co